Clicky

Resverlogix Corp(RVXCF)

Description: Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.


Keywords: Medicine Diabetes Cardiovascular Disease Kidney Disease Chronic Kidney Disease Neurodegenerative Diseases Kidney Chronic Condition Degenerative Disease Diabetes Mellitus Renal Disease Artery Artery Disease Orphan Disease Chronic Kidney Neurodegenerative Disease Esv Peripheral Artery Disease Renal Diseases Talon Bromodomain Rvx 208

Home Page: www.resverlogix.com

4820 Richard Road SW
Calgary, AB T3E 6L1
Canada
Phone: 403 254 9252


Officers

Name Title
Mr. Donald J. McCaffrey Co-Founder, Chairman, Pres, CEO & Sec.
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV Chief Financial Officer
Dr. Ewelina Kulikowski Ph.D. Chief Scientific Officer
Dr. Jan O. Johansson M.D., Ph.D. Sr. VP of Medical Affairs
Dr. Michael Sweeney M.D. Sr. VP of Clinical Devel.
Sarah Zapotichny Director of Investor Relations & Corp. Communications

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: April
Full Time Employees: 22
Back to stocks